Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Patient randomization nearly complete in MN-166 trial for ALS

Summary by ALS News Today
Patient randomization is nearly complete in Medicinova’s Phase 2b/3 COMBAT-ALS trial testing MN-166 (ibudilast) for the treatment of ALS.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

ALS News TodayALS News Today

Patient randomization nearly complete in MN-166 trial for ALS

Patient randomization is nearly complete in Medicinova’s Phase 2b/3 COMBAT-ALS trial testing MN-166 (ibudilast) for the treatment of ALS.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

ALS News Today broke the news in on Tuesday, July 29, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Maryland icon

Maryland

News
For You
SearchBlindspotLocal